Fresenius disposes of Schiwa:
This article was originally published in Clinica
Executive Summary
German dialysis specialist Fresenius is to sell Schiwa, its infusion solution manufacturer, to B Braun Melsungen. Fresenius bought Schiwa from BASF subsidiary Knoll in 1992 but met with opposition from the German Kartellamt (monopolies commission). The Kartellamt ruled in October last year that the merger would lead to an overly dominant position in the German infusion and dialysis products market (see Clinica No 678, p 15).
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.